Physician profile
Kenneth P Patrick
NPI 1548249394
$1,188.53
in general payments reported to CMS, 2019-2025
17 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.18 · 2020: $31.95 · 2021: $86.66 · 2022: $180 · 2023: $186 · 2024: $293 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $387.27 | 2019-2025 | Vanflyta, Injectafer, Enhertu |
| Janssen Biotech, INC. | $293.76 | 2021-2025 | Erleada, Darzalex, Imbruvica |
| Merck Sharp & Dohme LLC | $126.68 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $48.30 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $43.15 | 2024 | Givlaari |
| Exelixis INC. | $40.71 | 2024-2025 | Cabometyx |
| Eisai INC. | $36.90 | 2023-2025 | |
| Gilead Sciences, INC. | $31.99 | 2022-2023 | |
| Edwards Lifesciences Corporation | $25.08 | 2021 | |
| Incyte Corporation | $24.54 | 2024 | Pemazyre, Monjuvi |
| Tesaro, INC. | $23.92 | 2019 | |
| Celgene Corporation | $22.60 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.84 | 2024 | |
| Glaxosmithkline, LLC. | $19.98 | 2025 | Ojjaara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.99 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $14.15 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.67 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.